Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.74 USD | -0.21% | +8.52% | -8.70% |
May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Financials (USD)
Sales 2021 | 172M | Sales 2022 | 317M | Capitalization | 380M |
---|---|---|---|---|---|
Net income 2021 | -8M | Net income 2022 | 35M | EV / Sales 2021 | 3.44 x |
Net cash position 2021 | 67.84M | Net Debt 2022 | 10.19M | EV / Sales 2022 | 1.23 x |
P/E ratio 2021 |
-77
x | P/E ratio 2022 |
10.7
x | Employees | 134 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 65.14% |
Latest transcript on Eagle Pharmaceuticals, Inc.
1 week | +13.37% | ||
Current month | +16.14% | ||
1 month | -5.00% | ||
3 months | -10.71% | ||
6 months | -65.33% | ||
Current year | -9.18% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Graves
CEO | Chief Executive Officer | 61 | 13-10-31 |
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 07-02-28 |
Ryan Debski
CMP | Compliance Officer | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 07-02-28 |
Jennifer Simpson
BRD | Director/Board Member | 55 | 19-08-27 |
Richard Edlin
BRD | Director/Board Member | 63 | 17-03-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.54% | 0 M€ | -2.03% | ||
0.25% | 0 M€ | -3.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 4.775 | +0.53% | 9 034 |
24-05-08 | 4.75 | 0.00% | 69,831 |
24-05-07 | 4.75 | +3.94% | 83,278 |
24-05-06 | 4.57 | +3.63% | 167,853 |
24-05-03 | 4.41 | +0.23% | 51,307 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-9.18% | 61.69M | |
+6.77% | 72.03B | |
-10.86% | 5.14B | |
+46.43% | 4.6B | |
+5.38% | 3.96B | |
-16.20% | 2.5B | |
+21.35% | 2.43B | |
-26.20% | 2.32B | |
+19.92% | 2.18B | |
+8.15% | 1.72B |
- Stock Market
- Equities
- EGRX Stock